Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer.
Recurrent, locally advanced, unresectable or metastatic breast cancer with disease progression following anti-estrogen therapy.
Prior treatment with at least 2 chemotherapy regimens:
* At least 1 of these regimens must have been administered in the metastatic setting.
* At least 1 of these regimens must have contained a taxane.
* No more than 2 prior chemotherapy regimens in the metastatic setting.
Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group scale.
Have discontinued all previous therapies for cancer.
Have the presence of measureable disease as defined by Response Evaluation Criteria in Solid Tumors Version 1.1.
You may not be if
Have either a history of central nervous system (CNS) metastasis or evidence of CNS metastasis on the magnetic resonance image of brain obtained at baseline.
Received prior therapy with another cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor.
Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug.
Have had major surgery within 14 days of the initial dose of study drug.
Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).
Clareo Health | A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
